This Article Full Text Full Text (PDF) Other Versions of this Article: JVI.00335-08v1 82/13/6576    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Mesquita, P. M. M. Articles by Shattock, R. J. PubMed PubMed Citation Articles by Mesquita, P. M. M. Articles by Shattock, R. J.

 Previous Article  |  Next Article 

Journal of Virology, July 2008, p. 6576-6584, Vol. 82, No. 13
0022-538X/08/$08.00+0     doi:10.1128/JVI.00335-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Candidate Microbicide PPCM Blocks Human Immunodeficiency Virus Type 1 Infection in Cell and Tissue Cultures and Prevents Genital Herpes in a Murine Model

Department of Cellular and Molecular Medicine, St. George's University of London, London, United Kingdom,¹ Departments of Pediatrics,² Microbiology and Immunology,³ Medicine, Albert Einstein College of Medicine, Bronx, New York⁴

Received 15 February 2008/ Accepted 16 April 2008

A structurally novel candidate microbicide, PPCM, which is formed from the reaction of D,L-mandelic acid with sulfuric acid, provides activity against human immunodeficiency virus (HIV) and herpes simplex virus (HSV) and is not cytotoxic. The objectives of the current studies were to comprehensively evaluate the activity of PPCM in cell and explant cultures, explore the possibility of combining PPCM with HIV-specific reverse transcriptase inhibitors, and evaluate the efficacy of a formulated gel against genital herpes in a murine model. PPCM inhibited infection by laboratory and clinical R5 and X4 clade B and clade C HIV strains in cell culture. Ectocervical and endocervical tissue explants exposed to HIV-1_BaL in the presence of PPCM were protected (50% inhibitory concentrations [IC₅₀] of 3.9 µg/ml for ectocervix and 3.1 µg/ml for endocervix), and transfer of virus to target T cells via migratory cells was significantly impaired (IC₅₀ of 35.7 µg/ml for ectocervix and 54.6 µg/ml for endocervix). The drug also blocked infection by cell-associated virus. Combinations of PPCM with UC-781 or PMPA in vitro exhibited additive anti-HIV activity. PPCM was incorporated into stable, low-pH gel formulations at concentrations of 0.4% and 4%. Both gels prevented genital herpesvirus infection in mice, even when virus was introduced in human seminal plasma. The abilities of PPCM to inhibit primary HIV isolates, reduce infection by cell-associated virus, and transfer of HIV from migratory to T cells, combined with the complete protection provided by formulated gel against genital herpes, indicate that this drug is an excellent candidate for inclusion in a combination microbicide and would provide protection against both HIV and HSV.

Published ahead of print on 23 April 2008.